Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia
| Autor: | Anna Christofides, Versha Banerji, Sarah Doucette, Andrew Aw, Laurie H. Sehn, Susan A. Robinson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Canada
Chronic lymphocytic leukemia B-cell receptor Review Article Disease 03 medical and health sciences 0302 clinical medicine immune system diseases Chemoimmunotherapy first-line therapy hemic and lymphatic diseases Agammaglobulinaemia Tyrosine Kinase Humans Medicine Bruton's tyrosine kinase In patient 030212 general & internal medicine Bruton tyrosine kinase inhibitors Protein Kinase Inhibitors frontline therapy biology business.industry medicine.disease Leukemia Lymphocytic Chronic B-Cell Hedgehog signaling pathway Leukemia 030220 oncology & carcinogenesis biology.protein Cancer research chronic lymphocytic leukemia untreated disease Immunotherapy business |
| Zdroj: | Curr Oncol Current Oncology Volume 27 Issue 6 Pages 6795-655 |
| ISSN: | 1718-7729 |
| DOI: | 10.3747/co.27.6795 |
| Popis: | Chronic lymphocytic leukemia (cll) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of cll between patients results in variable disease trajectories and responses to therapy. Notably, compared with patients lacking high-risk features, those with such features&mdash such as deletions in chromosome 17p, aberrations in the TP53 gene, or unmutated immunoglobulin heavy chain variable region genes&mdash experience inferior outcomes and responses to standard chemoimmunotherapy. Novel agents that target the B cell receptor signalling pathway, such as Bruton tyrosine kinase (btk) inhibitors, have demonstrated clinical efficacy and safety in patients with treatment-naï ve cll, particularly those with high-risk features. However, given the current lack of head-to-head trials comparing btk inhibitors, selection of the optimal btk inhibitor for patients with cll is unclear and requires consideration of multiple factors. In the present review, we focus on the efficacy, safety, and pharmacologic features of the btk inhibitors that are approved or under clinical development, and we discuss the practical considerations for the use of those agents in the Canadian treatment landscape. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|